RenovoRx, Inc.
RNXTNASDAQHealthcare● Active
$0.90
+$0.02(+1.91%)
Market Cap$33595562
P/E Ratio—
52W High$1.45
52W Low$0.701
RenovoRx, Inc. (RNXT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RNXT · earnings · updated Jun 10, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$0.08
Est. -$0.08 · +0.0%
Revenue
$0.00B
Est. $0.00B · +19.9%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▲ Beat Revenue🔥 11-Quarter EPS Beat Streak
RNXT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Next earnings date not yet announced.
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.08 | — | — | — | $0.00B | — |
| — Q2 FY2026 | May 14, 2026 | -$0.08 | -$0.08 | +0.0% | $0.00B | $0.00B | +19.9% |
| — Q1 FY2026 | Mar 30, 2026 | -$0.08 | -$0.08 | +0.0% | $0.00B | $0.00B | -43.3% |
| — Q4 FY2025 | Nov 13, 2025 | -$0.08 | -$0.08 | +0.0% | $0.00B | $0.00B | -34.4% |
| — Q3 FY2025 | Aug 14, 2025 | -$0.08 | -$0.08 | +0.0% | $0.00B | $0.00B | +38.8% |
| — Q2 FY2025 | May 15, 2025 | -$0.08 | -$0.08 | +0.0% | $0.00B | $0.00B | +7.5% |
| ▲ Q1 FY2025 | Mar 31, 2025 | -$0.13 | -$0.12 | +7.7% | $0.00B | $0.00B | -74.3% |
| ▲ Q4 FY2024 | Nov 13, 2024 | -$0.12 | -$0.10 | +16.7% | — | — | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.08
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026
EPS Actual
-$0.08
EPS Est.
-$0.08
EPS Surpr.
+0.0%
Revenue
$0.00B
Q1 FY2026
Mar 30, 2026
EPS Actual
-$0.08
EPS Est.
-$0.08
EPS Surpr.
+0.0%
Revenue
$0.00B
Q4 FY2025
Nov 13, 2025
EPS Actual
-$0.08
EPS Est.
-$0.08
EPS Surpr.
+0.0%
Revenue
$0.00B
Q3 FY2025
Aug 14, 2025
EPS Actual
-$0.08
EPS Est.
-$0.08
EPS Surpr.
+0.0%
Revenue
$0.00B
Q2 FY2025
May 15, 2025
EPS Actual
-$0.08
EPS Est.
-$0.08
EPS Surpr.
+0.0%
Revenue
$0.00B
Q1 FY2025
Mar 31, 2025Beat
EPS Actual
-$0.12
EPS Est.
-$0.13
EPS Surpr.
+7.7%
Revenue
$0.00B
Q4 FY2024
Nov 13, 2024Beat
EPS Actual
-$0.10
EPS Est.
-$0.12
EPS Surpr.
+16.7%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.03 | $-0.02 | $-0.01 | 1 |
| Q3 FY2027 | $-0.04 | $-0.03 | $-0.02 | 1 |
| Q2 FY2027 | $-0.06 | $-0.04 | $-0.03 | 1 |
| Q1 FY2027 | $-0.07 | $-0.05 | $-0.03 | 1 |
| Q4 FY2026 | $-0.09 | $-0.07 | $-0.04 | 1 |
| Q3 FY2026 | $-0.06 | $-0.05 | $-0.04 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 14, 2026 | +0.0% | $0.85 | $0.86 | +0.75% |
| ▲ Q1 FY2026 | Mar 30, 2026 | +0.0% | $1.13 | $1.07 | -5.31% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +0.0% | $1.00 | $0.97 | -2.56% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +0.0% | $1.22 | $1.24 | +1.64% |
| ▲ Q2 FY2025 | May 15, 2025 | +0.0% | $1.05 | $1.11 | +5.71% |
| ▲ Q1 FY2025 | Mar 31, 2025 | +7.7% | $1.00 | $0.99 | -1.00% |
| ▲ Q4 FY2024 | Nov 13, 2024 | +16.7% | $1.10 | $1.09 | -0.91% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +0.0% | $1.14 | $1.16 | +1.75% |
Q2 FY2026+0.75%
Report Date
May 14, 2026
EPS Beat/Miss
+0.0%
Price Before
$0.85
Price After
$0.86
Q1 FY2026-5.31%
Report Date
Mar 30, 2026
EPS Beat/Miss
+0.0%
Price Before
$1.13
Price After
$1.07
Q4 FY2025-2.56%
Report Date
Nov 13, 2025
EPS Beat/Miss
+0.0%
Price Before
$1.00
Price After
$0.97
Q3 FY2025+1.64%
Report Date
Aug 14, 2025
EPS Beat/Miss
+0.0%
Price Before
$1.22
Price After
$1.24
Q2 FY2025+5.71%
Report Date
May 15, 2025
EPS Beat/Miss
+0.0%
Price Before
$1.05
Price After
$1.11
Q1 FY2025-1.00%
Report Date
Mar 31, 2025
EPS Beat/Miss
+7.7%
Price Before
$1.00
Price After
$0.99
Q4 FY2024-0.91%
Report Date
Nov 13, 2024
EPS Beat/Miss
+16.7%
Price Before
$1.10
Price After
$1.09
Q3 FY2024+1.75%
Report Date
Aug 13, 2024
EPS Beat/Miss
+0.0%
Price Before
$1.14
Price After
$1.16
Avg Beat Reaction+0.01%
Beat Rate8 / 8 quarters
Largest Move+5.71% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RNXT ends December
RenovoRx, Inc. (RNXT) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-0.08 (in line with the analyst consensus of $-0.08). RNXT has beaten EPS estimates for 11 consecutive quarters.
Each quarter, investors track RNXT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RNXT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RNXT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RNXT earnings · 4 questionsRenovoRx, Inc.'s next earnings report is expected around TBD. RNXT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RNXT historically reports after market close (AMC).
RNXT earnings datewhen is RNXT earningsRNXT next earnings datewhen does RNXT report earningsRNXT earnings calendar
▸ Source: FMP · RenovoRx, Inc. SEC filings · US GAAP · RenovoRx, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 10, 2026